Vitamin D3 (Cholecalciferol)
Last reviewed
Vitamin D3 is a fat-soluble hormone that regulates calcium, supports immune function, and stabilizes mast cells. About 51% of POTS patients run deficient; correcting the deficit produces mast cell stabilization and autonomic support that supplementation studies have repeatedly shown. ZebraThrive uses 2,000 IU daily, paired with K2 to route calcium correctly.
At a Glance
Daily Dose
2,000 IU (50 mcg) daily
Key Benefits
How It Works
Vitamin D3 acts as a neuroactive hormone with profound effects on multiple systems. In POTS patients, it modulates autonomic nervous system function-deficiency correlates with decreased heart rate variability and impaired baroreflex sensitivity. It enhances β-adrenergic signal transduction in cardiac cells and regulates the renin-angiotensin system.
For MCAS, vitamin D3 works as a mast cell stabilizer. Mast cells express both vitamin D receptors (VDR) and the enzyme CYP27B1, enabling local conversion to active calcitriol. Through VDR-dependent mechanisms, it suppresses histamine release and reduces inflammatory mediators including leukotrienes, TNF-α, and IL-6.
In connective tissue, vitamin D influences the hydroxylation processes essential for stable collagen cross-linking, working synergistically with vitamin C and iron. High deficiency rates in hEDS (60%) and POTS (51%) make supplementation particularly relevant.
What the Research Shows
Strong direct evidence from pediatric studies shows significant symptom improvement with supplementation.
RCT, n=65 pediatric POTS patients
74% improved with 800 IU/day; POTS patients had markedly lower baseline 25(OH)D levels.
Large meta-analysis confirms deficiency significantly increases orthostatic intolerance risk.
Meta-analysis, 16,326 patients
Vitamin D deficiency associated with 36% higher orthostatic hypotension risk (OR 1.36).
Mechanistic studies demonstrate D3 suppresses activation through receptor-mediated pathways.
D3 suppresses IgE-dependent mast cell activation, reducing histamine release by 23-34%.
Addressing the Triad
Tailored benefits for complex conditions
Vitamin D acts as a hormone through the VDR (vitamin D receptor) on mast cells: at adequate levels, it reduces degranulation, lowers IL-4 production, and dampens FcεRI signaling in lab studies. The clinical picture is paradoxical though - MCAS cohorts often have better D status than the general population, which argues against simple deficiency as a primary MCAS driver. The European expert consensus still recommends supplementation in mastocytosis/MCAS based on mechanism rather than deficiency correction. Our position: at 2,000 IU, the mast cell mechanisms are operative at clinically relevant levels.
For hEDS, vitamin D matters for connective tissue maintenance, especially tendon and bone. Korean studies in surgical tendon repair showed 3-times higher retear rates in D-deficient patients. Wound healing RCTs show nearly 2-times faster healing with D3 supplementation. Bone density data in EDS populations consistently shows higher fracture rates that correlate with D status. The direct EDS intervention trials don't exist yet, but the prevalence data is clear: D deficiency is more common in EDS, and the downstream tissues that fail in EDS (tendons, bones, skin) all show D-dependent repair signaling. Foundational ingredient.
This is where vitamin D earns its place in the formulation. A 2025 Chinese RCT in 65 pediatric POTS patients found 74% symptom improvement with 800 IU daily for 2 months - the strongest direct POTS evidence for any ingredient on this list. A Brazilian study at 7,000 IU showed improved heart rate variability. A meta-analysis of 16,326 patients found D-deficient people had 36% higher risk of orthostatic hypotension. The mechanism is multifactorial - VDR on autonomic neurons, calcium handling in vascular smooth muscle, anti-inflammatory effects. The evidence converges.
Why We Chose This Form
We use D3 (cholecalciferol) rather than D2 (ergocalciferol) - D3 raises blood levels of the active 25(OH)D form more efficiently and durably (meta-analyses consistently favor D3 over D2 for repletion). The 2,000 IU dose is the standard daily supplement amount: high enough to maintain sufficiency in most adults, low enough to remain conservative for daily long-term use. We pair D3 with K2 in the same AM capsule because K2 directs calcium handling - D3 increases calcium absorption, and K2 ensures it ends up in bones and teeth rather than soft tissues. Take with breakfast fat for absorption.
Form Comparison
D3 (Cholecalciferol)
3-5x more potent than D2; preferred form
D2 (Ergocalciferol)
Inferior bioavailability; shorter half-life
Oil-based liquid/capsule delivery
30-50% better absorption than dry powder; descriptive of our delivery format
Safety & Interactions
Potential Side Effects
Generally well-tolerated. Hypercalcemia is possible at very high doses (>10,000 IU) without monitoring. Some patients report initial paradoxical reactions, often excipient-related.
Drug Interactions
No direct interactions with common POTS/MCAS meds. H2 blockers may slightly reduce absorption (space by 2 hours). Thiazide diuretics require calcium monitoring.
Excipients to Avoid
- FD&C dyes
- Titanium dioxide
- Carrageenan
- Corn starch
- BHA/BHT
Safe Excipients
- MCT oil
- Olive oil
- Minimal-ingredient liquid drops
Monitor serum 25(OH)D levels (target 40-60 ng/mL). Check serum calcium if taking high doses (>4,000 IU).
How to Start
| Protocol Step | Suggested Dosage | Key Notes |
|---|---|---|
| Weeks 1-2 | 1,000 IU daily | Ultra-sensitive start |
| Weeks 3-4 | 2,000 IU daily | Standard maintenance |
| Ongoing | 2,000-4,000 IU daily | Adjust based on labs |
"Repletion takes 8-12 weeks; symptom improvement usually seen within 2-3 months. Take with fat-containing meal."
State of the Evidence
No direct RCTs specifically in adult hEDS, POTS, or MCAS populations. Some findings are counterintuitive (e.g., higher vitamin D status in some MCAS cohorts). All autonomic benefits are extrapolated primarily from pediatric and diabetic populations.
- [1]Vitamin D supplementation in pediatric POTSPMID: 40962545
Dong et al. (2025)
- [2]Vitamin D deficiency and orthostatic hypotension meta-analysisPMID: 34628636
Zuin et al. (2022)
- [3]Vitamin D suppresses IgE-dependent mast cell activationPMID: 27998003
Liu et al. (2017)
- [4]Vitamin D and autonomic functionPMID: 38747749
Faria et al. (2024)
- [5]Vitamin D deficiency in vascular EDSPMID: 27488172
Busch et al. (2016)
Common Questions
Written by Ken Chapman, Founder of ZebraThrive. Reviewed and last updated .